Innoviva Profit Margin 2010-2023 | INVA

Current and historical gross margin, operating margin and net profit margin for Innoviva (INVA) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Innoviva net profit margin as of December 31, 2023 is 57.89%.
Innoviva Annual Profit Margins
Innoviva Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.929B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.775B 118.03
Novo Nordisk (NVO) Denmark $550.845B 45.38
Johnson & Johnson (JNJ) United States $351.202B 13.93
Merck (MRK) United States $317.211B 83.49
AbbVie (ABBV) United States $291.555B 14.82
AstraZeneca (AZN) United Kingdom $211.944B 18.78
Novartis AG (NVS) Switzerland $196.211B 13.59
Pfizer (PFE) United States $143.772B 13.87
Sanofi (SNY) $114.819B 10.34